AbbVie submitted a New Drug Application to the U.S. Food and Drug Administration for ABBV-951 (foscarbidopa/foslevodopa) for the treatment of motor fluctuations in patients with advanced Parkinson’s disease.
Parkinson’s Foundation Announces Major Expansion of PD GENEration Study, Increasing Access to Genetic Testing and Counseling Across the U.S.
CNS Disorders, Gene Testing, Genetic Testing, Genomic Tests, Neurodegenerative Disorders, Parkinson's, Parkinson's Disease, Parkinson's Disease, Parkinson's Disease, Parkinson’s disease, Parkinson’s Disease, Parkinson’s disease, Parkinson’s disease, Personalization, Personalized Care, Personalized health, Personalized Medicine, Personalized TherapeuticsThe Parkinson’s Foundation has announced the expansion of PD GENEration: Mapping the Future of Parkinson’s Disease, a first-of-its-kind national initiative offering genetic testing and counseling for people with Parkinson’s disease (PD) at no cost.
Theravance Narrows Focus to Multiple System Atrophy Subset Following Mixed Results
Clinical Trials, Low Blood Pressure, Multiple system atrophy (MSA), Neurogenic orthostatic hypotension (nOH), Parkinson's Disease, Parkinson’s disease, R&D, Rare Disorders, Serotonin And Norepinephrine Reuptake Inhibitors, TherapeuticsTheravance Biopharma announced mixed results from a study evaluating the use of ampreloxetine to reduce symptomatic neurogenic orthostatis hypotension (nOH).
Research Roundup: Spider Silk Stabilizes Cancer-Suppressing Protein and More
Asthma, Autism Spectrum Disorder (ASD), Cancer Cells, Cancer Therapies, Coronavirus Disease 2019 (COVID-19), Gene Mutations, Heart Attacks, Heart Disease, High Cholesterol, Karolinska Institute, Medical Journals, Parkinson's Disease, Pediatrics, Proteins, R&D, Skin test, Structure, TestingMaybe Spider-Man was on to something. Although spider silk and synthetic forms have been used for a wide range of applications – including bullet-proof clothing, biodegradable bottles, and bandages and surgical thread – new research suggests it may have a use for cancer therapies.
Research Roundup: Neurons Key to Parkinson’s ID’ed, New ALS Mechanism Discovered
Amyotrophic Lateral Sclerosis (ALS), Brain Stem, Cardiovascular Disease, COVID-19 Vaccines, Diabetes, Diet, Efficacy, Frontotemporal Dementia (FTD), Gut, Immune System, Johns Hopkins, National Institutes of Health, Neurons, Obesity, Parkinson's Disease, R&D, Severe Covid-19Researchers at the University of Copenhagen – The Faculty of Health and Medical Sciences found that activating a specialized group of neurons within the brainstem of mice restored full movement function in mice with symptoms of Parkinson’s disease.
Arkuda Therapeutics secured $64 million in Series B financing. This adds to the $44 million Series A the company achieved in November 2019.
Scientists have pondered possible linkages between COVID-19 and the onset of Parkinson’s disease for more than a year, and a new report published in ACS Chemical Neuroscience details that correlation.
Supernus Pharmaceuticals Inc. is acquiring Adamas Pharmaceuticals Inc. for about $400 million as the Rockville, Maryland-based company is expanding its portfolio of treatments for Parkinson’s disease and reducing reliance on the drugmaker’s top-selling epilepsy medicine, Trokendi XR.
Swiss pharma giant Roche announced a partnership with Shape Therapeutics valued at more than $3 billion that will attempt to harness the Seattle-based company’s RNA editing platform to take on neurodegenerative diseases as well as others.
GlaxoSmithKline Plc and U.S. firm Alector Inc. will together develop antibody-based treatments for Parkinson’s, Alzheimer’s and other similar diseases in a deal worth up to $2.2 billion, the drugmakers said on July 2.